Skip to main content
Journal cover image

Defining the risk of SARS-CoV-2 variants on immune protection.

Publication ,  Journal Article
DeGrace, MM; Ghedin, E; Frieman, MB; Krammer, F; Grifoni, A; Alisoltani, A; Alter, G; Amara, RR; Baric, RS; Barouch, DH; Bloom, JD; Boon, ACM ...
Published in: Nature
May 2022

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants jeopardizes the protective antiviral immunity induced after infection or vaccination. To address the public health threat caused by the increasing SARS-CoV-2 genomic diversity, the National Institute of Allergy and Infectious Diseases within the National Institutes of Health established the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme. This effort was designed to provide a real-time risk assessment of SARS-CoV-2 variants that could potentially affect the transmission, virulence, and resistance to infection- and vaccine-induced immunity. The SAVE programme is a critical data-generating component of the US Government SARS-CoV-2 Interagency Group to assess implications of SARS-CoV-2 variants on diagnostics, vaccines and therapeutics, and for communicating public health risk. Here we describe the coordinated approach used to identify and curate data about emerging variants, their impact on immunity and effects on vaccine protection using animal models. We report the development of reagents, methodologies, models and notable findings facilitated by this collaborative approach and identify future challenges. This programme is a template for the response to rapidly evolving pathogens with pandemic potential by monitoring viral evolution in the human population to identify variants that could reduce the effectiveness of countermeasures.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

May 2022

Volume

605

Issue

7911

Start / End Page

640 / 652

Location

England

Related Subject Headings

  • Virulence
  • United States
  • SARS-CoV-2
  • Pharmacogenomic Variants
  • Pandemics
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Humans
  • General Science & Technology
  • COVID-19 Vaccines
  • COVID-19
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DeGrace, M. M., Ghedin, E., Frieman, M. B., Krammer, F., Grifoni, A., Alisoltani, A., … Suthar, M. S. (2022). Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 605(7911), 640–652. https://doi.org/10.1038/s41586-022-04690-5
DeGrace, Marciela M., Elodie Ghedin, Matthew B. Frieman, Florian Krammer, Alba Grifoni, Arghavan Alisoltani, Galit Alter, et al. “Defining the risk of SARS-CoV-2 variants on immune protection.Nature 605, no. 7911 (May 2022): 640–52. https://doi.org/10.1038/s41586-022-04690-5.
DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, et al. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022 May;605(7911):640–52.
DeGrace, Marciela M., et al. “Defining the risk of SARS-CoV-2 variants on immune protection.Nature, vol. 605, no. 7911, May 2022, pp. 640–52. Pubmed, doi:10.1038/s41586-022-04690-5.
DeGrace MM, Ghedin E, Frieman MB, Krammer F, Grifoni A, Alisoltani A, Alter G, Amara RR, Baric RS, Barouch DH, Bloom JD, Bloyet L-M, Bonenfant G, Boon ACM, Boritz EA, Bratt DL, Bricker TL, Brown L, Buchser WJ, Carreño JM, Cohen-Lavi L, Darling TL, Davis-Gardner ME, Dearlove BL, Di H, Dittmann M, Doria-Rose NA, Douek DC, Drosten C, Edara V-V, Ellebedy A, Fabrizio TP, Ferrari G, Fischer WM, Florence WC, Fouchier RAM, Franks J, García-Sastre A, Godzik A, Gonzalez-Reiche AS, Gordon A, Haagmans BL, Halfmann PJ, Ho DD, Holbrook MR, Huang Y, James SL, Jaroszewski L, Jeevan T, Johnson RM, Jones TC, Joshi A, Kawaoka Y, Kercher L, Koopmans MPG, Korber B, Koren E, Koup RA, LeGresley EB, Lemieux JE, Liebeskind MJ, Liu Z, Livingston B, Logue JP, Luo Y, McDermott AB, McElrath MJ, Meliopoulos VA, Menachery VD, Montefiori DC, Mühlemann B, Munster VJ, Munt JE, Nair MS, Netzl A, Niewiadomska AM, O’Dell S, Pekosz A, Perlman S, Pontelli MC, Rockx B, Rolland M, Rothlauf PW, Sacharen S, Scheuermann RH, Schmidt SD, Schotsaert M, Schultz-Cherry S, Seder RA, Sedova M, Sette A, Shabman RS, Shen X, Shi P-Y, Shukla M, Simon V, Stumpf S, Sullivan NJ, Thackray LB, Theiler J, Thomas PG, Trifkovic S, Türeli S, Turner SA, Vakaki MA, van Bakel H, VanBlargan LA, Vincent LR, Wallace ZS, Wang L, Wang M, Wang P, Wang W, Weaver SC, Webby RJ, Weiss CD, Wentworth DE, Weston SM, Whelan SPJ, Whitener BM, Wilks SH, Xie X, Ying B, Yoon H, Zhou B, Hertz T, Smith DJ, Diamond MS, Post DJ, Suthar MS. Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022 May;605(7911):640–652.
Journal cover image

Published In

Nature

DOI

EISSN

1476-4687

Publication Date

May 2022

Volume

605

Issue

7911

Start / End Page

640 / 652

Location

England

Related Subject Headings

  • Virulence
  • United States
  • SARS-CoV-2
  • Pharmacogenomic Variants
  • Pandemics
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Humans
  • General Science & Technology
  • COVID-19 Vaccines
  • COVID-19